Alan Arakkal

Alan Arakkal

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
AMAaron C. Miller
Aaron C. Miller
AAAlan Arakkal
Alan Arakkal
SKScott Koeneman
Scott Koeneman
Joseph CavanaughJoseph Cavanaugh
Joseph Cavanaugh
George ThompsonGeorge Thompson
George Thompson
PPPhilip M Polgreen
Philip M Polgreen
Histoplasmosis is often confused with other diseases leading to diagnostic delays. We estimated the incidence, length of, and risk factors for, diagnostic delays associated with histoplasmosis. Using data from IBM Marketscan, 2001–2017, we found all patients with a histoplasmosis diagnosis. We calculated the number of visits that occurred prior to the histoplasmosis diagnosis and the number of visits with symptomatically similar diagnoses (SSDs). Next, we estimated the number of visits that represented a delay using a simulation-based approach. We also computed the number of potential opportunities for diagnosis that were missed for each patient and the length of time between the first opportunity and the diagnosis. Finally, we identified risk factors for diagnostic delays using a logistic regression model. The number of SSD-related visits increased significantly in the 97 days prior to the histoplasmosis diagnosis. During this period, 97.4% of patients had a visit, and 90.1% had at least one SSD visit. We estimate that 82.9% of patients with histoplasmosis experienced at least one missed diagnostic opportunity. The average delay was 39.5 days with an average of 4.0 missed opportunities. Risk factors for diagnostic delays included prior antibiotic use, history of other pulmonary diseases, and emergency department and outpatient visits, especially during weekends. New diagnostic approaches for histoplasmosis are needed.

13 April 2020 in Injury Epidemiology
Verified
Journal Article
Open access
PDF file
AAAlan Arakkal
Alan Arakkal
ABAnna E. Barón
Anna E. Barón
MLMolly M Lamb
Molly M Lamb
SFSarah Fields
Sarah Fields
RCR. Dawn Comstock
R. Dawn Comstock
Background: Traumatic brain injury legislation varies across states. A comprehensive nationwide evaluation of state traumatic brain injury laws is vital given growing populations of high school athletes. This study evaluates the effectiveness of traumatic brain injury laws by examining longitudinal trends in incident and recurrent concussion rates and determines if state level variations in legislation’s language affected the observed trends. Methods: In this retrospective ecological study of a large national sample of US high schools from 2005/06 through 2017/18, piecewise regression models along with a profile likelihood approach were utilized to examine longitudinal trends in incident and recurrent concussion rates. Results: Overall incident concussion rates increased by an additional 1.85%/standardized month (STDM) (95% confidence interval (CI): 1.14, 2.56%) prior to law passage and decreased by an additional 1.08%/ STDM (95%CI: − 1.43, − 0.72%) after law passage. Similar trends were observed for overall recurrent concussion rates. Among states that specified the category of healthcare provider for return to play clearance, post-law recurrent concussion rates decreased on average by an additional 1.59%/STDM (95%CI: − 3.42, 0.22%) compared to states that did not specify the category of healthcare provider. Conclusions: The passage of state level traumatic brain injury laws was associated with an increase in overall incident and recurrent concussion rates prior to law passage and a decrease in rates after law passage. Although not statistically significant, states with traumatic brain injury laws specifying the category of healthcare provider for return to play clearance had a greater rate of decline in post-law recurrent concussion rates compared to states not specifying the category of healthcare provider. The findings suggest that state traumatic brain injury laws may benefit from specifying the category of healthcare provider allowed to provide return to play clearance, if they do not already include such language.

2 April 2025 in Critical Care Explorations
Verified
Journal Article
Open access
RSRoger D. Struble
Roger D. Struble
AAAlan Arakkal
Alan Arakkal
Joseph CavanaughJoseph Cavanaugh
Joseph Cavanaugh
PPPhilip M Polgreen
Philip M Polgreen
AMAaron C. Miller
Aaron C. Miller
IMPORTANCE: Delays in diagnosing sepsis may increase morbidity and mortality, but the frequency of delays is poorly understood. OBJECTIVES: The aim of this study was to estimate the frequency and duration of diagnostic delays for sepsis and potential risk factors for delay. DESIGN, SETTING, AND PARTICIPANTS: We conducted a retrospective case-crossover analysis of sepsis cases from 2016 to 2019 using claims from Merative MarketScan. We ascertained the index diagnosis of sepsis and corresponding hospitalization. We analyzed healthcare visits in the 180 days before diagnosis and then compared the observed and expected trends in signs or symptoms of infection, immune or organ dysfunction (e.g., fever, dyspnea) during the 14 days before diagnosis. A bootstrapping approach was used to estimate the frequency and duration of potential diagnostic delays along with possible risk-factors for experiencing a delay. MAIN OUTCOMES AND MEASURES: The number of patients who experienced a potential diagnostic delay, duration of delay, and number of potential missed opportunities. RESULTS: We identified a total of 649,756 cases of sepsis from 2016 to 2019 meeting inclusion criteria. There was an increase in visits with signs or symptoms of infection, immune or organ dysfunction just before the index diagnosis of sepsis. We estimated that around 16.57% (95% CI, 16.38–16.78) of patients experienced a potential diagnostic delay, with a mean delay duration of 3.21 days (95% CI, 3.13–3.27) and a median of 2 days. Most delays occurred in outpatient settings. Potential diagnostic delays were more frequent among younger age groups and patients who received antibiotics (odds ratio [OR] 2.58 [95% CI, 2.54–2.62]), or treatments for particular symptoms, including opioids (OR 1.43 [95% CI, 1.40–1.46]) and inhalers (OR 1.37 [95% CI, 1.33–1.40]). CONCLUSIONS AND RELEVANCE: There may be a substantial number of potential missed opportunities to diagnose sepsis, especially in outpatient settings. Multiple factors might contribute to delays in diagnosing sepsis including commonly prescribed medications for symptoms.

14 November 2023 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Open access
AAAlan Arakkal
Alan Arakkal
LPLinnea A. Polgreen
Linnea A. Polgreen
CCCole G. Chapman
Cole G. Chapman
JSJacob Simmering
Jacob Simmering
Joseph CavanaughJoseph Cavanaugh
Joseph Cavanaugh
AMAaron C. Miller
Aaron C. Miller
Background: Prescription opioids have contributed to the rise in opioid‐related overdoses and deaths. The presence of opioids within households may increase the risk of overdose among family members who were not prescribed an opioid themselves. Larger quantities of opioids may further increase risk.Objectives: To determine the risk of opioid overdose among individuals who were not prescribed an opioid but were exposed to opioids prescribed to other family members in the household, and evaluate the risk in relation to the total morphine milligram equivalents (MMEs) present in the household.Methods: We conducted a cohort study using a large database of commercial insurance claims from 2001 to 2021. For inclusion in the cohort, we identified individuals not prescribed an opioid in the prior 90 days from households with two or more family members, and determined the total MMEs prescribed to other family members. Individuals were stratified into monthly enrollment strata defined by household opioid exposure and other confounders. A generalized linear model was used to estimate incidence rate ratios (IRRs) for overdose.Results: Overall, the incidence of overdose among enrollees in households where a family member was prescribed an opioid was 1.73 (95% confidence interval [CI]: 1.67–1.78) times greater than households without opioid prescriptions. The risk of overdose increased continuously with the level of potential MMEs in the household from an IRR of 1.23 (95% CI: 1.16–1.32) for 1–100 MMEs to 4.67 (95% CI: 4.18–5.22) for >12,000 MMEs. The risk of overdose associated with household opioid exposure was greatest for ages 1–2 years (IRR: 3.46 [95% CI: 2.98–4.01]) and 3–5 years (IRR: 3.31 [95% CI: 2.75–3.99]).Conclusions: The presence of opioids in a household significantly increases the risk of overdose among other family members who were not prescribed an opioid. Higher levels of MMEs, either in terms of opioid strength or quantity, were associated with increased levels of risk. Risk estimates may reflect accidental poisonings among younger family members.

6 February 2026
Verified
Dataset
Closed access
DSDaniel Sewell
Daniel Sewell
AAAlan Arakkal
Alan Arakkal
Perform fundamental analyses using Bayesian parametric and non-parametric inference (regression, anova, 1 and 2 sample inference, non-parametric tests, etc.). (Practically) no Markov chain Monte Carlo (MCMC) is used; all exact finite sample inference is completed via closed form solutions or else through posterior sampling automated to ensure precision in interval estimate bounds. Diagnostic plots for model assessment, and key inferential quantities (point and interval estimates, probability of direction, region of practical equivalence, and Bayes factors) and model visualizations are provided. Bayes factors are computed either by the Savage Dickey ratio given in Dickey (1971) or by Chib's method as given in xxx. Interpretations are from Kass and Raftery (1995) . ROPE bounds are based on discussions in Kruschke (2018) . Methods for determining the number of posterior samples required are described in Doss et al. (2014) . Bayesian model averaging is done in part by Feldkircher and Zeugner (2015) . Methods for contingency table analysis is described in Gunel et al. (1974) . Variational Bayes (VB) methods are described in Salimans and Knowles (2013) . Mediation analysis uses the framework described in Imai et al. (2010) . The loss-likelihood bootstrap used in the non-parametric regression modeling is described in Lyddon et al. (2019) . Non-parametric survival methods are described in Qing et al. (2023) . Methods used for the Bayesian Wilcoxon signed-rank analysis is given in Chechile (2018) and for the Bayesian Wilcoxon rank sum analysis in Chechile (2020) . Correlation analysis methods are carried out by Barch and Chechile (2023) , and described in Lindley and Phillips (1976) and Chechile and Barch (2021) . See also Chechile (2020, ISBN: 9780262044585).

2 June 2025 in Computational Statistics & Data Analysis
Verified
Journal Article
Closed access
AAAlan Arakkal
Alan Arakkal
DSDaniel Sewell
Daniel Sewell